Ovarian cancer treatment reality in northern Rheinland- Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival

Onkologie

Volumn 30, Issue 12, 2007, Pages 611-617

  Weide, Rudolf ^a,b   Arndt, Margit ^a   Pandorf, Annette ^a   Heymanns, Jochen ^a   Thomalla, Jörg ^a   Köppler, Hubert ^a  

^a Praxisklinik fur Hamatologie und Onkologie   (Germany)

^b NONE   (Germany)

Author keywords

Ovarian cancer; Rheinland Pfalz; Treatment reality

Indexed keywords

CARBOPLATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; GERMANY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE CARE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG THERAPY; FEMALE; GERMANY; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 37049007677     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110093     Document Type: Article

References (32)

1. Tumorregister München: www.krebsinfo. de/ki/epidaten/tab719html (Stand 2001).
2. Krebs in Deutschland: 4. überarbeitete, aktualisierte Ausgabe Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Saarbrücken 2004.
3. Pfisterer J, du Bois A: Das Ovarialkarzinom. Therapeutische Standards, klinische Empfehlungen. Stuttgart, Georg Thieme Verlag, 2002.
4. Heintz APM, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HYS, Pecorelli S: Carcinoma of the ovary. 25th FIGO annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 2003;83(suppl 1):135-166.
5. Clark TG, Stewart ME, Altmann DG, Gabra H: A prognostic model for ovarian cancer. Br J Cancer 2001;85:944-952.
6. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B: Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 2003;101:885-891.
7. Grossi M, Quinn MA, Thursfield VJ, Francis PA, Rome RM, Planner RS, Giles GG: Ovarian cancer: patterns of care in Victoria during 1993-1995. Med J Aust 2002;177:11-16.
8. O'Malley CD, Cress RD, Campleman SL, Leiserowitz GS: Survival of californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 2003;91:608-615.
9. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM: Primary cytoreductive surgery for epithelian ovarian cancer. Obstet Gynecol 1983;61:413-420.
10. Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Sheperd JH, Gore ME: Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767-775.
11. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence free interval and survival in small volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166.
12. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C: Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000;78:21-27.
13. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Therapierichtlinien zur Behandlung maligner Ovarialtumoren. Interdiszipinäre Kurzgefasste Leitlinien der Deutschen Krebsgesellschaft und der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe. 3. Auflage, 2002.
14. Trimbos JB: Staging of early ovarian cancer and the impact of lymph node sampling. Int J Gynecol Cancer 2000;10:8-11.
15. Sakurai S, Shimizu Y, Utsugi K, Umezawa S, Kato T, Fukasawa I, Inaba N, Hasumi K: Validity of complete paraaortic and pelvic lymphadenopathy in apparent stage I (pT1) ovarian carcinoma. Proc Am Soc Clin Oncol 2002;21:201a.
16. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP: Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-3076.
17. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:1010-1014.
18. Vogl SE, Pagano M, Kaplan BH, Greenwald E, Arseneau J, Bennett B: Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potential only in women with small tumor burdens. Cancer 1983;51:2024-2030.
19. Eisenkop SM, Nalick RH, Wang HJ, Teng NN: Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993;51:224-229.
20. Michel G, De Iaco P, Castaigne D, el-Hassan MJ, Lobreglio R, Lhomme C, Rey A, Duvillard P: Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1997;18:9-15.
21. Hunter RW, Alexander ND, Soutter WP: Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504-511.
22. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: Survival effect of maximal cytoreductive surgery for ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259.
23. Du Bois A, Pfisterer J, Kellermann L: Die Therapie des fortgeschrittenen Ovarialkarzinomes in Deutschland. Gynäkologie 2001;34:1029-1040.
24. Ries LA: Ovarian cancer. Survival and treatment differences by age. Cancer 1993;71:524-529.
25. Munoz KA, Harlan LC, Trimble EL: Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997;15:3408-3415.
26. Lee CK, Pires de Miranda M, Ledermann JA, Ruiz de Elvira MC, Nelstrop AE, Lambert HE, Rustin GJS, Trask CWL: Outcome of epithelial ovarian cancer in women under 40 years of age treated with platinum-based chemotherapy. Eur J Cancer 1999;35:727-732.
27. Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI: Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002;20:173-178.
28. Silverberg SG: Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000;19:7-15.
29. Mayr D, Diebold J: Grading of ovarian carcinomas. Int J Gynecol Pathol 2000;19:348-353.
30. Pfisterer J, Hilpert F, du Bois A, Meier W, Wagner U: State-of-the-art first-line treatment of ovarian cancer. Onkologie 2003;26:446-450.
31. Du Bois A, Rochon J, Lamparter C, Pfisterer J: AGO Organkommission OVAR Pfisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 2005;15:183-191.
32. Sehouli J, Kostromitskaia J, Stengel D, Du Bois A: Why institutions do not participate in ovarian cancer trials - results from a survey in Germany. Onkologie 2005;28:13-17